



Clinical trial results:

A Phase II, Randomized, Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of Elbasvir/Grazoprevir (EBR/GZR) and Sofosbuvir (SOF) with and without Ribavirin (RBV) in Cirrhotic Subjects with Chronic HCV GT3 Infection

Summary

EudraCT number	2015-003187-37
Trial protocol	GB
Global end of trial date	06 January 2017

Results information

Result version number	v1 (current)
This version publication date	02 December 2017
First version publication date	02 December 2017

Trial information

Trial identification

Sponsor protocol code	5172-083
-----------------------	----------

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02332707
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Merck Sharp & Dohme Corp.
Sponsor organisation address	2000 Galloping Hill Road, Kenilworth, NJ, United States, 07033
Public contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com
Scientific contact	Clinical Trials Disclosure, Merck Sharp & Dohme Corp., ClinicalTrialsDisclosure@merck.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	06 January 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	06 January 2017
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

This is a randomized, multi-site, open-label trial of the co-administration of a fixed-dose combination (FDC) of EBR 50 mg + GZR (100 mg) (EBR/GZR) and SOF 400 mg, with and without RBV, in treatment-naïve (TN) and treatment-experienced (TE) participants with chronic hepatitis C virus (HCV) genotype 3 (GT3) infection with compensated cirrhosis.

Protection of trial subjects:

This study was conducted in conformance with Good Clinical Practice standards and applicable country and/or local statutes and regulations regarding ethical committee review, informed consent, and the protection of human subjects participating in biomedical research.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	05 January 2016
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 100
Worldwide total number of subjects	100
EEA total number of subjects	100

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	91
From 65 to 84 years	9
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

Adult participants infected with HCV GT3 were enrolled at 14 study centers in the United Kingdom.

Pre-assignment

Screening details:

A total of 101 participants were randomized, including 1 participant who did not meet inclusion criteria and who should have been considered a screen failure; this participant was not treated with study drug. A total of 100 participants were treated.

Period 1

Period 1 title	Overall Study (overall period)
Is this the baseline period?	Yes
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks

Arm description:

Treatment-naïve (TN) Hepatitis C virus (HCV) genotype 3 (GT3) participants took 1 fixed-dose combination (FDC) tablet containing elbasvir (EBR) 50 mg + grazoprevir (GZR) 100 mg and 1 tablet containing sofosbuvir (SOF) 400 mg once daily (q.d.) with ribavirin (RBV) (200 mg capsules; weight-based dosing) twice daily (b.i.d.) for 8 weeks.

Arm type	Experimental
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken once daily (q.d.) by mouth in the morning.

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Rebetol®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).

Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi®, Harvoni®

Pharmaceutical forms	Tablet
Routes of administration	Oral use
Dosage and administration details:	
SOF 400 mg tablet taken q.d. by mouth in the morning with food.	

Arm title	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks
------------------	--

Arm description:

TN HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken once daily (q.d.) by mouth in the morning.

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi®, Harvoni®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Arm title	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks
------------------	--

Arm description:

Treatment-experienced (TE) HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken once daily (q.d.) by mouth in the morning.

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi®, Harvoni®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Arm title	Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks
------------------	--

Arm description:

TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken once daily (q.d.) by mouth in the morning.

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Investigational medicinal product name	Ribavirin
Investigational medicinal product code	
Other name	Rebetol®
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose ranging from 800 mg to 1400 mg (total daily dose was based on participant body weight).

Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi®, Harvoni®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Arm title	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks
------------------	--

Arm description:

TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.

Arm type	Experimental
----------	--------------

Investigational medicinal product name	Grazoprevir
Investigational medicinal product code	
Other name	MK-5172
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

GZR 100 mg is a component of the MK-5172A FDC tablet (also containing EBR 50 mg) and was taken once daily (q.d.) by mouth in the morning.

Investigational medicinal product name	Sofosbuvir
Investigational medicinal product code	
Other name	Sovaldi®, Harvoni®
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

SOF 400 mg tablet taken q.d. by mouth in the morning with food.

Investigational medicinal product name	Elbasvir
Investigational medicinal product code	
Other name	MK-8742
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

EBR 50 mg is a component of the MK-5172A FDC tablet (also containing GZR 100 mg) and was taken q.d. by mouth in the morning.

Number of subjects in period 1	Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks
Started	23	24	17
Completed	23	20	16
Not completed	0	4	1
Consent withdrawn by subject	-	1	-
Lost to follow-up	-	3	1

Number of subjects in period 1	Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks
Started	18	18
Completed	17	16
Not completed	1	2
Consent withdrawn by subject	1	-
Lost to follow-up	-	2

Baseline characteristics

Reporting groups

Reporting group title	Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks
Reporting group description: Treatment-naïve (TN) Hepatitis C virus (HCV) genotype 3 (GT3) participants took 1 fixed-dose combination (FDC) tablet containing elbasvir (EBR) 50 mg + grazoprevir (GZR) 100 mg and 1 tablet containing sofosbuvir (SOF) 400 mg once daily (q.d.) with ribavirin (RBV) (200 mg capsules; weight-based dosing) twice daily (b.i.d.) for 8 weeks.	
Reporting group title	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks
Reporting group description: TN HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.	
Reporting group title	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks
Reporting group description: Treatment-experienced (TE) HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.	
Reporting group title	Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks
Reporting group description: TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.	
Reporting group title	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks
Reporting group description: TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.	

Reporting group values	Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks
Number of subjects	23	24	17
Age categorical Units: Subjects			
Adults (18-64 years)	21	24	14
From 65-84 years	2	0	3
Age Continuous Units: Years			
arithmetic mean	52.5	48.1	58.6
standard deviation	± 9.0	± 9.3	± 6.1
Gender, Male/Female Units: Subjects			
Female	10	7	6
Male	13	17	11

Reporting group values	Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks	Total
Number of subjects	18	18	100
Age categorical Units: Subjects			
Adults (18-64 years)	15	17	91
From 65-84 years	3	1	9

Age Continuous			
Units: Years			
arithmetic mean	56.1	53.8	
standard deviation	± 8.4	± 6.4	-
Gender, Male/Female			
Units: Subjects			
Female	6	3	32
Male	12	15	68

End points

End points reporting groups

Reporting group title	Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks
Reporting group description: Treatment-naïve (TN) Hepatitis C virus (HCV) genotype 3 (GT3) participants took 1 fixed-dose combination (FDC) tablet containing elbasvir (EBR) 50 mg + grazoprevir (GZR) 100 mg and 1 tablet containing sofosbuvir (SOF) 400 mg once daily (q.d.) with ribavirin (RBV) (200 mg capsules; weight-based dosing) twice daily (b.i.d.) for 8 weeks.	
Reporting group title	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks
Reporting group description: TN HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.	
Reporting group title	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks
Reporting group description: Treatment-experienced (TE) HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.	
Reporting group title	Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks
Reporting group description: TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.	
Reporting group title	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks
Reporting group description: TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.	

Primary: Percentage of participants achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy)

End point title	Percentage of participants achieving SVR12 (Sustained Virologic Response 12 weeks after the end of all study therapy) ^[1]
End point description: The percentage of participants achieving SVR12 (i.e., HCV ribonucleic acid [RNA] < Lower Limit of Quantification [LLOQ] 12 weeks after completing study treatment) was determined. Plasma HCV RNA levels were determined with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. All randomized participants who received at least 1 dose of study drug, were not lost to follow-up for reasons unrelated to study treatment, and had SVR12 data available are included.	
End point type	Primary
End point timeframe: Up to Week 28	

Notes:

[1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, only descriptive statistics are presented.

End point values	Arm 1: HCV GT3 TN EBG/GZR+SOF+RBV 8 Weeks	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks	Arm 4: HCV GT3 TE EBG/GZR+SOF+RBV 12 Weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	23	17	17
Units: Percentage of Participants				

number (confidence interval 95%)	91.3 (72.0 to 98.9)	100.0 (85.2 to 100.0)	100.0 (80.5 to 100.0)	100.0 (80.5 to 100.0)
----------------------------------	---------------------	-----------------------	-----------------------	-----------------------

End point values	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Percentage of Participants				
number (confidence interval 95%)	94.4 (72.7 to 99.9)			

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants experiencing an adverse event (AE)

End point title	Percentage of participants experiencing an adverse event
-----------------	--

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. All participants who received at least 1 dose of study drug are included.

End point type	Primary
----------------	---------

End point timeframe:

Up to 18 weeks (up to 2 weeks after completion of study treatment)

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, only descriptive statistics are presented.

End point values	Arm 1: HCV GT3 TN EBG/GZR+SOF +RBV 8 Weeks	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks	Arm 4: HCV GT3 TE EBG/GZR+SOF +RBV 12 Weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	24	17	18
Units: Percentage of Participants				
number (not applicable)	87.0	87.5	82.4	94.4

End point values	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Percentage of Participants				

number (not applicable)	94.4			
-------------------------	------	--	--	--

Statistical analyses

No statistical analyses for this end point

Primary: Percentage of participants discontinuing from study therapy due to an AE

End point title	Percentage of participants discontinuing from study therapy due to an AE ^[3]
-----------------	---

End point description:

An AE is defined as any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. All participants who received at least 1 dose of study drug are included.

End point type	Primary
----------------	---------

End point timeframe:

Up to 16 weeks

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: Per protocol, only descriptive statistics are presented.

End point values	Arm 1: HCV GT3 TN EBG/GZR+SOF +RBV 8 Weeks	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks	Arm 4: HCV GT3 TE EBG/GZR+SOF +RBV 12 Weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	24	17	18
Units: Percentage of Participants				
number (not applicable)	0.0	0.0	0.0	0.0

End point values	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks			
Subject group type	Reporting group			
Number of subjects analysed	18			
Units: Percentage of Participants				
number (not applicable)	5.6			

Statistical analyses

No statistical analyses for this end point

Secondary: Percentage of participants achieving SVR24 (Sustained Virologic

Response 24 weeks after the end of all study therapy)

End point title	Percentage of participants achieving SVR24 (Sustained Virologic Response 24 weeks after the end of all study therapy)
-----------------	---

End point description:

The percentage of participants achieving SVR24 (i.e., HCV RNA < LLOQ 24 weeks after completing study treatment) was determined. Plasma HCV RNA levels were determined with the COBAS™ AmpliPrep/COBAS™ Taqman™ HCV Test, v2.0 ® assay, which has a LLOQ of 15 IU/mL. All randomized participants who received at least 1 dose of study drug, were not lost to follow-up for reasons unrelated to study treatment, and had SVR24 data available are included.

End point type	Secondary
----------------	-----------

End point timeframe:

Up to Week 40

End point values	Arm 1: HCV GT3 TN EBG/GZR+SOF +RBV 8 Weeks	Arm 2: HCV GT3 TN EBG/GZR+SOF 12 Weeks	Arm 3: HCV GT3 TE EBG/GZR+SOF 12 Weeks	Arm 4: HCV GT3 TE EBG/GZR+SOF +RBV 12 Weeks
Subject group type	Reporting group	Reporting group	Reporting group	Reporting group
Number of subjects analysed	23	21	16	17
Units: Percentage of Participants				
number (confidence interval 95%)	91.3 (72.0 to 98.9)	100.0 (83.9 to 100.0)	100.0 (79.4 to 100.0)	100.0 (80.5 to 100.0)

End point values	Arm 5: HCV GT3 TE EBG/GZR+SOF 16 Weeks			
Subject group type	Reporting group			
Number of subjects analysed	16			
Units: Percentage of Participants				
number (confidence interval 95%)	93.8 (69.8 to 99.8)			

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Up to 40 weeks

Adverse event reporting additional description:

All participants who received at least 1 dose of study drug are included.

Assessment type	Systematic
-----------------	------------

Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	19.1
--------------------	------

Reporting groups

Reporting group title	Arm 2: HCV GT3 TN EBR/GZR+SOF 12 weeks
-----------------------	--

Reporting group description:

TN HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.

Reporting group title	Arm 1: HCV GT3 TN EBR/GZR+SOF+RBV 8 Weeks
-----------------------	---

Reporting group description:

TN HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 8 weeks.

Reporting group title	Arm 4: HCV GT3 TE EBR/GZR+SOF+RBV 12 weeks
-----------------------	--

Reporting group description:

TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. with RBV (200 mg capsules; weight-based dosing) b.i.d. for 12 weeks.

Reporting group title	Arm 5: HCV GT3 TE EBR/GZR+SOF 16 weeks
-----------------------	--

Reporting group description:

TE HCV GT3 participants took 1 FDC tablet containing EBR 50 mg+GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 16 weeks.

Reporting group title	Arm 3: HCV GT3 TE EBR/GZR+SOF 12 weeks
-----------------------	--

Reporting group description:

Treatment-experienced (TE) HCV GT3 participants took 1 FDC tablet containing EBR 50 mg + GZR 100 mg and 1 tablet containing SOF 400 mg q.d. for 12 weeks.

Serious adverse events	Arm 2: HCV GT3 TN EBR/GZR+SOF 12 weeks	Arm 1: HCV GT3 TN EBR/GZR+SOF+RBV 8 Weeks	Arm 4: HCV GT3 TE EBR/GZR+SOF+RBV 12 weeks
Total subjects affected by serious adverse events			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	3 / 18 (16.67%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Investigations			
Creatinine renal clearance decreased			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			

Hepatocellular carcinoma			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Toxicity to various agents			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Wrist fracture			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
Chest pain			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Lung infection			

subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Arm 5: HCV GT3 TE EBR/GZR+SOF 16 weeks	Arm 3: HCV GT3 TE EBR/GZR+SOF 12 weeks	
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 18 (5.56%)	2 / 17 (11.76%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Investigations			
Creatinine renal clearance decreased			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Hepatocellular carcinoma			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Injury, poisoning and procedural complications			
Contusion			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Toxicity to various agents			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Wrist fracture			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			

Chest pain			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences causally related to treatment / all	0 / 0	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Respiratory, thoracic and mediastinal disorders			
Pulmonary embolism			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Cellulitis			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Lung infection			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences causally related to treatment / all	0 / 0	0 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Arm 2: HCV GT3 TN EBR/GZR+SOF 12 weeks	Arm 1: HCV GT3 TN EBR/GZR+SOF+RBV 8 Weeks	Arm 4: HCV GT3 TE EBR/GZR+SOF+RBV 12 weeks
Total subjects affected by non-serious adverse events			
subjects affected / exposed	21 / 24 (87.50%)	21 / 23 (91.30%)	17 / 18 (94.44%)
Vascular disorders			
Hypertension			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Peripheral coldness			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
General disorders and administration site conditions			
Chills			

subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	2 / 18 (11.11%) 2
Fatigue subjects affected / exposed occurrences (all)	8 / 24 (33.33%) 10	6 / 23 (26.09%) 6	10 / 18 (55.56%) 10
Feeling hot subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Influenza like illness subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	0 / 23 (0.00%) 0	0 / 18 (0.00%) 0
Oedema peripheral subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	0 / 18 (0.00%) 0
Pain subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Pyrexia subjects affected / exposed occurrences (all)	2 / 24 (8.33%) 2	0 / 23 (0.00%) 0	1 / 18 (5.56%) 2
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	1 / 23 (4.35%) 1	0 / 18 (0.00%) 0
Reproductive system and breast disorders Nipple pain subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	0 / 18 (0.00%) 0
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	1 / 23 (4.35%) 1	2 / 18 (11.11%) 2
Dysphonia			

subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dyspnoea			
subjects affected / exposed	1 / 24 (4.17%)	1 / 23 (4.35%)	3 / 18 (16.67%)
occurrences (all)	1	1	3
Dyspnoea exertional			
subjects affected / exposed	0 / 24 (0.00%)	3 / 23 (13.04%)	0 / 18 (0.00%)
occurrences (all)	0	3	0
Epistaxis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Oropharyngeal pain			
subjects affected / exposed	1 / 24 (4.17%)	1 / 23 (4.35%)	2 / 18 (11.11%)
occurrences (all)	1	1	2
Psychiatric disorders			
Anxiety			
subjects affected / exposed	0 / 24 (0.00%)	2 / 23 (8.70%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Depressed mood			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Depression			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Emotional disorder			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Euphoric mood			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Hallucination			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Insomnia			
subjects affected / exposed	0 / 24 (0.00%)	2 / 23 (8.70%)	0 / 18 (0.00%)
occurrences (all)	0	2	0

Irritability			
subjects affected / exposed	0 / 24 (0.00%)	2 / 23 (8.70%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Mood swings			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	3 / 18 (16.67%)
occurrences (all)	0	1	3
Panic attack			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Sleep disorder			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Investigations			
Blood potassium increased			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haemoglobin decreased			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	2 / 18 (11.11%)
occurrences (all)	0	0	2
Injury, poisoning and procedural complications			
Accidental overdose			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	3 / 18 (16.67%)
occurrences (all)	0	1	4
Skin abrasion			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Cardiac disorders			
Palpitations			
subjects affected / exposed	0 / 24 (0.00%)	2 / 23 (8.70%)	1 / 18 (5.56%)
occurrences (all)	0	2	1
Nervous system disorders			
Amnesia			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Disturbance in attention			

subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	1 / 18 (5.56%)
occurrences (all)	0	1	1
Dizziness			
subjects affected / exposed	3 / 24 (12.50%)	1 / 23 (4.35%)	3 / 18 (16.67%)
occurrences (all)	3	1	3
Dysgeusia			
subjects affected / exposed	1 / 24 (4.17%)	1 / 23 (4.35%)	1 / 18 (5.56%)
occurrences (all)	1	1	1
Headache			
subjects affected / exposed	7 / 24 (29.17%)	5 / 23 (21.74%)	11 / 18 (61.11%)
occurrences (all)	7	6	12
Hypersomnia			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hypoaesthesia			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Lethargy			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Memory impairment			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nystagmus			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Paraesthesia			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Sinus headache			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Syncope			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Tremor			

subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Hypoacusis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	0	1	0
Lacrimation increased			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Myopia			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Vision blurred			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Visual impairment			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	1	0	0
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	0 / 24 (0.00%)	2 / 23 (8.70%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Abdominal distension			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	2
Abdominal pain			
subjects affected / exposed	2 / 24 (8.33%)	0 / 23 (0.00%)	4 / 18 (22.22%)
occurrences (all)	2	0	4
Abdominal pain lower			

subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Abdominal pain upper			
subjects affected / exposed	2 / 24 (8.33%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	2	1	0
Ascites			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Constipation			
subjects affected / exposed	3 / 24 (12.50%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	3	1	0
Diarrhoea			
subjects affected / exposed	3 / 24 (12.50%)	1 / 23 (4.35%)	2 / 18 (11.11%)
occurrences (all)	4	1	2
Dry mouth			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Dyspepsia			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Flatulence			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Gastrooesophageal reflux disease			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Haemorrhoids			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Lip dry			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Mouth ulceration			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Nausea			

subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3	4 / 23 (17.39%) 4	6 / 18 (33.33%) 7
Oesophagitis subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	0 / 18 (0.00%) 0
Toothache subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	1 / 23 (4.35%) 1	0 / 18 (0.00%) 0
Vomiting subjects affected / exposed occurrences (all)	3 / 24 (12.50%) 3	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Hepatobiliary disorders Biliary colic subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Jaundice subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	2 / 18 (11.11%) 2
Skin and subcutaneous tissue disorders Alopecia subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Dry skin subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	2 / 23 (8.70%) 2	4 / 18 (22.22%) 4
Eczema subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	1 / 18 (5.56%) 1
Erythema subjects affected / exposed occurrences (all)	0 / 24 (0.00%) 0	0 / 23 (0.00%) 0	0 / 18 (0.00%) 0
Pruritus subjects affected / exposed occurrences (all)	1 / 24 (4.17%) 1	0 / 23 (0.00%) 0	5 / 18 (27.78%) 6
Rash			

subjects affected / exposed	1 / 24 (4.17%)	3 / 23 (13.04%)	3 / 18 (16.67%)
occurrences (all)	1	3	3
Skin irritation			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Skin lesion			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Renal and urinary disorders			
Nephrolithiasis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
Arthralgia			
subjects affected / exposed	0 / 24 (0.00%)	1 / 23 (4.35%)	3 / 18 (16.67%)
occurrences (all)	0	1	3
Back pain			
subjects affected / exposed	2 / 24 (8.33%)	1 / 23 (4.35%)	1 / 18 (5.56%)
occurrences (all)	2	1	1
Bone pain			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Costochondritis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Haemarthrosis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Joint effusion			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal chest pain			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal discomfort			

subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Musculoskeletal pain			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	1	0	1
Myalgia			
subjects affected / exposed	1 / 24 (4.17%)	0 / 23 (0.00%)	2 / 18 (11.11%)
occurrences (all)	2	0	2
Neck pain			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Pain in extremity			
subjects affected / exposed	0 / 24 (0.00%)	2 / 23 (8.70%)	0 / 18 (0.00%)
occurrences (all)	0	2	0
Infections and infestations			
Cellulitis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Conjunctivitis			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	0	0	1
Lower respiratory tract infection			
subjects affected / exposed	2 / 24 (8.33%)	1 / 23 (4.35%)	0 / 18 (0.00%)
occurrences (all)	2	1	0
Nasopharyngitis			
subjects affected / exposed	2 / 24 (8.33%)	1 / 23 (4.35%)	1 / 18 (5.56%)
occurrences (all)	2	1	1
Rhinitis			
subjects affected / exposed	2 / 24 (8.33%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	2	0	0
Upper respiratory tract infection			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0
Urinary tract infection			
subjects affected / exposed	2 / 24 (8.33%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	2	0	1

Metabolism and nutrition disorders			
Decreased appetite			
subjects affected / exposed	4 / 24 (16.67%)	0 / 23 (0.00%)	1 / 18 (5.56%)
occurrences (all)	4	0	1
Type 2 diabetes mellitus			
subjects affected / exposed	0 / 24 (0.00%)	0 / 23 (0.00%)	0 / 18 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Arm 5: HCV GT3 TE EBR/GZR+SOF 16 weeks	Arm 3: HCV GT3 TE EBR/GZR+SOF 12 weeks	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	17 / 18 (94.44%)	16 / 17 (94.12%)	
Vascular disorders			
Hypertension			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Peripheral coldness			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Chills			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Fatigue			
subjects affected / exposed	6 / 18 (33.33%)	6 / 17 (35.29%)	
occurrences (all)	6	6	
Feeling hot			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Influenza like illness			
subjects affected / exposed	2 / 18 (11.11%)	0 / 17 (0.00%)	
occurrences (all)	2	0	
Oedema peripheral			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Pain			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Pyrexia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 17 (5.88%) 1	
Immune system disorders Hypersensitivity subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Seasonal allergy subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Reproductive system and breast disorders Nipple pain subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 17 (5.88%) 1	
Dysphonia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Dyspnoea subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	
Dyspnoea exertional subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Epistaxis subjects affected / exposed occurrences (all)	2 / 18 (11.11%) 2	2 / 17 (11.76%) 2	
Oropharyngeal pain subjects affected / exposed occurrences (all)	4 / 18 (22.22%) 4	1 / 17 (5.88%) 2	
Psychiatric disorders			

Anxiety			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Depressed mood			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Depression			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Emotional disorder			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Euphoric mood			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Hallucination			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Insomnia			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Irritability			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Mood swings			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Panic attack			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Sleep disorder			
subjects affected / exposed	0 / 18 (0.00%)	2 / 17 (11.76%)	
occurrences (all)	0	2	
Investigations			
Blood potassium increased			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	
Haemoglobin decreased subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Injury, poisoning and procedural complications Accidental overdose subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	2 / 17 (11.76%) 3	
Skin abrasion subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Cardiac disorders Palpitations subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	
Nervous system disorders Amnesia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Disturbance in attention subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Dizziness subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Dysgeusia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Headache subjects affected / exposed occurrences (all)	7 / 18 (38.89%) 7	5 / 17 (29.41%) 7	
Hypersomnia subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Hypoaesthesia			

subjects affected / exposed	0 / 18 (0.00%)	2 / 17 (11.76%)	
occurrences (all)	0	3	
Lethargy			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Memory impairment			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Nystagmus			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Paraesthesia			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Sinus headache			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Syncope			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Tremor			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Ear and labyrinth disorders			
Ear pain			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Hypoacusis			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Eye disorders			
Dry eye			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Lacrimation increased			

subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Myopia			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Vision blurred			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Visual impairment			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal discomfort			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Abdominal distension			
subjects affected / exposed	0 / 18 (0.00%)	3 / 17 (17.65%)	
occurrences (all)	0	3	
Abdominal pain			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Abdominal pain lower			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Abdominal pain upper			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Ascites			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Constipation			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Diarrhoea			
subjects affected / exposed	3 / 18 (16.67%)	3 / 17 (17.65%)	
occurrences (all)	3	3	

Dry mouth			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Dyspepsia			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Flatulence			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Haemorrhoids			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Lip dry			
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)	
occurrences (all)	0	0	
Mouth ulceration			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	2	
Nausea			
subjects affected / exposed	3 / 18 (16.67%)	3 / 17 (17.65%)	
occurrences (all)	3	3	
Oesophagitis			
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)	
occurrences (all)	0	1	
Toothache			
subjects affected / exposed	1 / 18 (5.56%)	0 / 17 (0.00%)	
occurrences (all)	1	0	
Vomiting			
subjects affected / exposed	1 / 18 (5.56%)	1 / 17 (5.88%)	
occurrences (all)	1	1	
Hepatobiliary disorders			
Biliary colic			

subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Jaundice subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	1 / 17 (5.88%) 1	
Skin and subcutaneous tissue disorders			
Alopecia subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Dry skin subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 17 (5.88%) 1	
Eczema subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Erythema subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Pruritus subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 17 (5.88%) 1	
Rash subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	1 / 17 (5.88%) 2	
Skin irritation subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Skin lesion subjects affected / exposed occurrences (all)	0 / 18 (0.00%) 0	0 / 17 (0.00%) 0	
Renal and urinary disorders			
Nephrolithiasis subjects affected / exposed occurrences (all)	1 / 18 (5.56%) 1	0 / 17 (0.00%) 0	
Musculoskeletal and connective tissue disorders			

Arthralgia		
subjects affected / exposed	2 / 18 (11.11%)	2 / 17 (11.76%)
occurrences (all)	2	3
Back pain		
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	1
Bone pain		
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0
Costochondritis		
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	1
Haemarthrosis		
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0
Joint effusion		
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0
Musculoskeletal chest pain		
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0
Musculoskeletal discomfort		
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0
Musculoskeletal pain		
subjects affected / exposed	0 / 18 (0.00%)	1 / 17 (5.88%)
occurrences (all)	0	1
Myalgia		
subjects affected / exposed	1 / 18 (5.56%)	4 / 17 (23.53%)
occurrences (all)	1	5
Neck pain		
subjects affected / exposed	0 / 18 (0.00%)	0 / 17 (0.00%)
occurrences (all)	0	0
Pain in extremity		
subjects affected / exposed	1 / 18 (5.56%)	4 / 17 (23.53%)
occurrences (all)	1	4

<p>Infections and infestations</p> <p>Cellulitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p>	<p>0 / 17 (0.00%)</p> <p>0</p>	
<p>Conjunctivitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	<p>0 / 17 (0.00%)</p> <p>0</p>	
<p>Lower respiratory tract infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p>	<p>1 / 17 (5.88%)</p> <p>1</p>	
<p>Nasopharyngitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>2 / 18 (11.11%)</p> <p>2</p>	<p>1 / 17 (5.88%)</p> <p>1</p>	
<p>Rhinitis</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	<p>0 / 17 (0.00%)</p> <p>0</p>	
<p>Upper respiratory tract infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p>	<p>1 / 17 (5.88%)</p> <p>1</p>	
<p>Urinary tract infection</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p>	<p>0 / 17 (0.00%)</p> <p>0</p>	
<p>Metabolism and nutrition disorders</p> <p>Decreased appetite</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>1 / 18 (5.56%)</p> <p>1</p>	<p>0 / 17 (0.00%)</p> <p>0</p>	
<p>Type 2 diabetes mellitus</p> <p>subjects affected / exposed</p> <p>occurrences (all)</p>	<p>0 / 18 (0.00%)</p> <p>0</p>	<p>1 / 17 (5.88%)</p> <p>1</p>	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
11 December 2015	Amendment 01: The primary purposes of this amendment were to change the duration of contraception use and egg/sperm donation, to add criteria for discontinuation of RBV use, and to specify that SOF must be taken with food.
09 August 2016	Amendment 02: The primary purpose of this amendment was to update eligibility criteria for entry into the long-term follow-up (MK-5172-017) for participants who failed therapy in this study.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported